Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?Zacks Investment Research • 07/24/25
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia GravisGlobeNewsWire • 05/30/25
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/08/25
Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis TrialGlobeNewsWire • 04/08/25
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/01/25
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia GravisGlobeNewsWire • 01/27/25
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 TrialGlobeNewsWire • 12/03/24
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease SummitGlobeNewsWire • 11/21/24
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/07/24
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual MeetingGlobeNewsWire • 10/15/24
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?Zacks Investment Research • 10/04/24
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15GlobeNewsWire • 09/03/24
Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top EstimatesZacks Investment Research • 08/08/24
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other UpdatesZacks Investment Research • 07/03/24
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal MalikGlobeNewsWire • 07/02/24
Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T DrugsInvestors Business Daily • 07/02/24
Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage studyReuters • 07/02/24
Cartesian Therapeutics Announces $130 Million Private Placement Equity FinancingGlobeNewsWire • 07/02/24
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus ErythematosusGlobeNewsWire • 07/02/24